GlassScriptPhysician profile
Mazhar E Elamir
NPI 1972527950
$120,612.99
in general payments reported to CMS, 2019-2025
70 companies · $5,620 in 2025
The $5,620 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $36K · 2021: $20K · 2022: $17K · 2023: $26K · 2024: $15K · 2025: $5,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $4,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,925.00 |
| Food and Beverage | $4,957.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $112,662.97 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $641.35 | 2020-2025 | Breztri, Fasenra, Airsupra |
| Lilly USA, LLC | $638.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $537.48 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $496.94 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $450.88 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Gilead Sciences, INC. | $417.02 | 2019-2025 | |
| Novo Nordisk INC | $372.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $291.34 | 2019-2022 | |
| Mannkind Corporation | $261.47 | 2020-2025 | |
| Abbvie INC. | $209.21 | 2021-2025 | |
| Electromed, INC. | $187.12 | 2021-2025 | Smartvest |
| Insmed, INC. | $163.37 | 2022-2025 | Arikayce, Brinsupri |
| Amgen INC. | $151.88 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $146.71 | 2019-2022 |
Show all 69 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazhar Elamir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.